| AMSAODD | American Medical Society on Alcoholism and Other Drug Dependencies |
|---|---|
| AODP | alcohol and other drug problems |
| Nutcracker syndrome | the vein from the left kidney is obstructed by one of the major arteries leaving the aorta. It can c... |
| SS | disulfide; sacrosciatic; saline soak; saline solution; saliva sample; saliva substitute; Salmonella-... |
| ABC | absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a... |
D factor
| systemic therapy | <pharmacology> Treatment that reaches and affects cells all over the body. (16 Dec 1997) |
|---|---|
| systemic vascular resistance | An index of arteriolar compliance or constriction throughout the body; equal to the blood pressure divided by the cardiac output. (05 Mar 2000) |
| systemic venous hypertension | Increased pressure in the veins ultimately leading to the right atrium nearly always due to disease of the right heart but occasionally due to blockade of one or both venae cavae. (05 Mar 2000) |
| juvenile chronic arthritis, systemic-onset | See: Juvenile rheumatoid arthritis, systemic-onset (still's disease). (12 Dec 1998) |
| juvenile rheumatoid arthritis, systemic-onset | Also known as systemic-onset juvenile chronic arthritis. Still's disease presents with systemic (bodywide) illness including high intermittent fever, a salmon-coloured skin rash, swollen lymph glands, enlargement of the liver and spleen, and inflammation of the lungs (pleuritis) and around the heart (pericarditis). The arthritis may not be immediately apparent but it does always surface and it may persists long after the systemic symptoms are gone. (12 Dec 1998) |
| lupus erythematosus, systemic | A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterised principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown aetiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of le cells in the blood or bone marrow. (12 Dec 1998) |
| abortifacient agents | Chemical substances that interrupt pregnancy after implantation. (12 Dec 1998) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| abortifacient agents, steroidal | Steroidal compounds with abortifacient activity. (12 Dec 1998) |
| adrenergic agents | Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (12 Dec 1998) |
| alkylating agents | Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (12 Dec 1998) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |
| anti-arrhythmia agents | Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (12 Dec 1998) |
| anti-asthmatic agents | Drugs that are used to treat asthma. (12 Dec 1998) |